RxDoctor Payments Data

Anselmo Humaran, MD

General Practice · Miami, FLNPI 1114038023

Payments from drug & device makers

$7,161in general payments, 2019–2025

Across 92 payments — averaging $77.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • GSK$1K
  • AstraZeneca$1K
  • Johnson & Johnson$717
  • Esperion Therapeutics, Inc.$629
  • Sunovion Pharmaceuticals Inc.$397
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$7,161100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,161 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$14,474
Medicare patients
30
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TradjentaLinagliptin26$20,945
TrintellixVortioxetine Hydrobromide24$17,190
EliquisApixaban17$10,819
LinzessLinaclotide19$10,291
FarxigaDapagliflozin Propanediol11$6,242
VascepaIcosapent Ethyl11$3,799
Fluticasone Propionate HfaFluticasone Propionate12$2,749
Tadalafil12$1,982
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,794
Gabapentin56$517
Bupropion XlBupropion Hcl47$455
ClopidogrelClopidogrel Bisulfate33$374
Diclofenac Sodium22$366
Fluticasone Propionate69$352
SsdSilver Sulfadiazine13$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta$1,247$20,94526 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14$17,19024 claims
PfizerEliquis$184$10,81917 claims
AbbVieLinzess$125$10,29119 claims
AstraZenecaFarxiga$1,098$6,24211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →